Hulio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0045 
B.II.b.2.c.1 - Change to importer, batch release 
30/11/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
adalimumab 
T/0044 
Transfer of Marketing Authorisation 
03/08/2023 
30/08/2023 
SmPC, 
Labelling and 
PL 
R/0041 
Renewal of the marketing authorisation. 
25/05/2023 
03/08/2023 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of Hulio 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IAIN/0043 
B.II.b.1.a - Replacement or addition of a 
24/05/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0039 
B.II.f.1.b.z - Stability of FP - Extension of the shelf 
05/12/2022 
03/08/2023 
SmPC and PL 
life of the finished product - Other variation 
IA/0040/G 
This was an application for a group of variations. 
30/11/2022 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0038 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/09/2022 
03/08/2023 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0037 
C.I.11.z - Introduction of, or change(s) to, the 
13/07/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0036 
B.II.z - Quality change - Finished product - Other 
29/06/2022 
n/a 
variation 
IA/0035/G 
This was an application for a group of variations. 
24/03/2022 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0034/G 
This was an application for a group of variations. 
28/02/2022 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
T/0033 
Transfer of Marketing Authorisation 
18/10/2021 
15/11/2021 
SmPC, 
Labelling and 
PL 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0032/G 
This was an application for a group of variations. 
29/09/2021 
15/11/2021 
SmPC, 
Labelling and 
PL 
B.IV.1.b - Change of a measuring or administration 
device - Deletion of a device 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.IV.1.b - Change of a measuring or administration 
device - Deletion of a device 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 4/12 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0031 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
27/08/2021 
15/11/2021 
SmPC and PL 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0030 
B.I.z - Quality change - Active substance - Other 
09/08/2021 
n/a 
variation 
IB/0029 
B.II.d.1.z - Change in the specification parameters 
09/07/2021 
n/a 
and/or limits of the finished product - Other variation 
IB/0028/G 
This was an application for a group of variations. 
16/06/2021 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IB/0027 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
15/06/2021 
15/11/2021 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0026/G 
This was an application for a group of variations. 
03/05/2021 
04/06/2021 
SmPC, 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0025 
A.7 - Administrative change - Deletion of 
02/03/2021 
04/06/2021 
Annex II and 
manufacturing sites 
PL 
X/0016 
Annex I_2.(c) Change or addition of a new 
15/10/2020 
14/12/2020 
SmPC, 
strength/potency 
Labelling and 
PL 
II/0021 
B.II.d.1.e - Change in the specification parameters 
10/12/2020 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0024 
B.I.a.2.a - Changes in the manufacturing process of 
08/12/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0023/G 
This was an application for a group of variations. 
11/11/2020 
n/a 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0022 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/10/2020 
14/12/2020 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
adalimumab 
IB/0019/G 
This was an application for a group of variations. 
23/07/2020 
n/a 
B.I.e.5.c - Implementation of changes foreseen in an 
approved change management protocol - For a 
biological/immunological medicinal product 
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product 
IAIN/0020 
B.IV.1.a.1 - Change of a measuring or administration 
15/07/2020 
n/a 
device - Addition or replacement of a device which is 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
not an integrated part of the primary packaging - 
Device with CE marking 
IAIN/0018/G 
This was an application for a group of variations. 
10/04/2020 
n/a 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/02/2020 
14/12/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0014/G 
This was an application for a group of variations. 
20/12/2019 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0012/G 
This was an application for a group of variations. 
08/11/2019 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
IAIN/0013/G 
This was an application for a group of variations. 
18/10/2019 
19/11/2019 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0010/G 
This was an application for a group of variations. 
12/09/2019 
n/a 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
IB/0011 
B.I.a.1.z - Change in the manufacturer of AS or of a 
13/08/2019 
19/11/2019 
Annex II and 
starting material/reagent/intermediate for AS - Other 
PL 
variation 
PSUSA/10589
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
adalimumab (biosimilars) 
II/0009 
C.I.11.b - Introduction of, or change(s) to, the 
14/06/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
II/0004 
C.I.13 - Other variations not specifically covered 
11/04/2019 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
10/04/2019 
19/11/2019 
SmPC, Annex 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II and PL 
II/0001 
B.II.b.2.b - Change to importer, batch release 
17/01/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/01/2019 
19/11/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0006/G 
This was an application for a group of variations. 
19/12/2018 
19/11/2019 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
B.II.e.5.a.2 - Change in pack size of the finished 
14/12/2018 
19/11/2019 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0002 
B.II.b.2.a - Change to importer, batch release 
07/11/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
 
